Free Trial

Kanabo Group (KNB) Competitors

GBX 1.55
0.00 (0.00%)
(As of 05/31/2024 ET)

KNB vs. TLY, SPI, MGP, SBI, MED, MTPH, COS, C4XD, DDDD, and RENX

Should you be buying Kanabo Group stock or one of its competitors? The main competitors of Kanabo Group include Totally (TLY), Spire Healthcare Group (SPI), Medica Group (MGP), Sourcebio International (SBI), Intelligent Ultrasound Group plc (MED.L) (MED), Biodexa Pharmaceuticals (MTPH), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), and Renalytix (RENX). These companies are all part of the "medical" sector.

Kanabo Group vs.

Totally (LON:TLY) and Kanabo Group (LON:KNB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation, earnings and community ranking.

38.3% of Totally shares are owned by institutional investors. Comparatively, 3.8% of Kanabo Group shares are owned by institutional investors. 12.4% of Totally shares are owned by company insiders. Comparatively, 45.3% of Kanabo Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Totally has higher revenue and earnings than Kanabo Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Totally£121.20M0.11£1.78MN/AN/A
Kanabo Group£1K9,802.67-£7.99M-£0.01-155.00

Totally presently has a consensus target price of GBX 30, suggesting a potential upside of 344.44%. Given Kanabo Group's higher probable upside, equities research analysts plainly believe Totally is more favorable than Kanabo Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Totally
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Kanabo Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Kanabo Group has a net margin of 0.00% compared to Kanabo Group's net margin of -0.80%. Kanabo Group's return on equity of -2.72% beat Totally's return on equity.

Company Net Margins Return on Equity Return on Assets
Totally-0.80% -2.72% 0.30%
Kanabo Group N/A -80.16%-18.89%

Totally has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Comparatively, Kanabo Group has a beta of 3.15, suggesting that its share price is 215% more volatile than the S&P 500.

Totally received 129 more outperform votes than Kanabo Group when rated by MarketBeat users.

CompanyUnderperformOutperform
TotallyOutperform Votes
129
72.47%
Underperform Votes
49
27.53%
Kanabo GroupN/AN/A

In the previous week, Totally had 1 more articles in the media than Kanabo Group. MarketBeat recorded 1 mentions for Totally and 0 mentions for Kanabo Group. Totally's average media sentiment score of 0.00 beat Kanabo Group's score of -0.20 indicating that Kanabo Group is being referred to more favorably in the news media.

Company Overall Sentiment
Totally Neutral
Kanabo Group Neutral

Summary

Totally beats Kanabo Group on 9 of the 15 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KNB vs. The Competition

MetricKanabo GroupMedical Care Facilities IndustryMedical SectorLON Exchange
Market Cap£9.80M£1.25B£5.13B£1.69B
Dividend YieldN/A4.04%2.75%6.86%
P/E Ratio-155.00155.16167.031,949.66
Price / Sales9,802.6761,279.792,422.34352,435.88
Price / Cash1.8212.0335.2526.47
Price / Book1.552.035.532.95
Net Income-£7.99M£43.19M£106.01M£166.54M
7 Day Performance-3.13%1.96%1.14%0.16%
1 Month Performance-16.22%3.43%1.43%6.65%
1 Year Performance-39.22%-2.38%4.07%17.74%

Kanabo Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TLY
Totally
1.7977 of 5 stars
GBX 6.55
-1.6%
GBX 30
+358.4%
-64.1%£12.86M£121.20M-515.001,668
SPI
Spire Healthcare Group
0.7525 of 5 stars
GBX 249.80
-0.7%
GBX 302.25
+21.0%
+13.5%£1.01B£1.36B3,568.5912,787High Trading Volume
MGP
Medica Group
0 of 5 stars
GBX 211
flat
N/A+0.0%£259.85M£76.98M3,516.67222
SBI
Sourcebio International
0 of 5 stars
GBX 115
+4.5%
N/A+0.0%£85.31M£75.61M1,277.78194Gap Up
High Trading Volume
MED
Intelligent Ultrasound Group plc (MED.L)
0 of 5 stars
GBX 14.50
-3.3%
N/A+0.0%£39.06M£5.28M-7.6345Gap Down
MTPH
Biodexa Pharmaceuticals
0 of 5 stars
GBX 18
+1,794.7%
N/A+0.0%£31.20M£645,000.00-21.9518Gap Up
COS
Collagen Solutions plc (COS.L)
0 of 5 stars
GBX 6.63
flat
N/A+0.0%£30.99M£4.01M-8.2848
C4XD
C4X Discovery
0 of 5 stars
GBX 12
+27.3%
N/A-29.2%£30.27M£24.68M300.0049High Trading Volume
DDDD
4D pharma
0 of 5 stars
GBX 16.66
flat
N/A+0.0%£30.05M£718,000.00-1.08106
RENX
Renalytix
0 of 5 stars
GBX 20
+5.3%
N/A-80.7%£29.51M£2.41M-66.67102Gap Down

Related Companies and Tools

This page (LON:KNB) was last updated on 6/1/2024 by MarketBeat.com Staff

From Our Partners